Although cost-effectiveness analysis has a long tradition of supporting healthcare decision-
making in Sweden, there are no clear criteria for when an intervention is considered too …

When healthcare interventions prolong life, people consume medical and non-medical
goods during the years of life they gain. It has been argued that the costs for medical …

Aim The aim of this study was to assess the impact on the cost-effectiveness ratio of
including measures of production and consumption following a health care or health …

New medical technologies that prolong life result in additional health care use in life years
gained. Some of these costs in life years gained are considered to be related to the …

Objectives A consensus has been reached in The Netherlands that all future medical costs
should be included in economic evaluations. Furthermore, internationally, there is the …

New technologies may displace existing, higher‐value care under a fixed budget. Countries
aim to curtail adoption of low‐value technologies, for example, by installing cost …

Purpose Value-based pricing of new, innovative health technologies defined as pricing
through economic evaluation requires the use of a basic cost-effectiveness threshold. This …

Objectives In many countries, future unrelated medical costs occurring during life-years
gained are excluded from economic evaluation, and benefits of unrelated medical care are …

Each study design has differing strengths and weaknesses, depending on data availability,
time, and budget constraints [2–4]. The FDA and other drug regulatory agencies mandate …

Aim To elicit reference values of medical and non-medical health care utilisation and costs
in Germany from a societal perspective. Methods 5007 telephone interviews were …